129 related articles for article (PubMed ID: 22391706)
1. Early dynamic PET/CT and 18F-FDG blood flow imaging in bladder cancer detection: a novel approach.
Belakhlef S; Church C; Jani C; Lakhanpal S
Clin Nucl Med; 2012 Apr; 37(4):366-8. PubMed ID: 22391706
[TBL] [Abstract][Full Text] [Related]
2. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?
Yang Z; Cheng J; Pan L; Hu S; Xu J; Zhang Y; Wang M; Zhang J; Ye D; Zhang Y
Ann Nucl Med; 2012 Aug; 26(7):571-7. PubMed ID: 22763630
[TBL] [Abstract][Full Text] [Related]
3. The effect of furosemide dose timing on bladder activity in oncology imaging with 18F-fluorodeoxyglucose PET/CT.
Nijjar S; Patterson J; Ducharme J; Leslie WD; Demeter SJ
Nucl Med Commun; 2010 Feb; 31(2):167-72. PubMed ID: 19997041
[TBL] [Abstract][Full Text] [Related]
4. Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
Yildirim-Poyraz N; Ozdemir E; Uzun B; Turkolmez S
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):214-21. PubMed ID: 23218514
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies.
Vicente AM; Castrejón AS; Muñoz AP; Woll PP; García AN
J Nucl Med Technol; 2010 Sep; 38(3):128-37. PubMed ID: 20807854
[TBL] [Abstract][Full Text] [Related]
6. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
7. Absence of urine production due to renal failure enables clear visualization of primary urinary bladder carcinoma on 18F-FDG PET/CT.
Bertagna F; Motta F; Fisogni S; Lena MS; Lucchini S; Giubbini R
Clin Nucl Med; 2012 Jun; 37(6):611-3. PubMed ID: 22614202
[TBL] [Abstract][Full Text] [Related]
8. Proposal of a new acquisition protocol for bladder cancer visualization with 18F-FDG PET/CT.
Chondrogiannis S; Marzola MC; Colletti PM; Rubello D
Clin Nucl Med; 2015 Jan; 40(1):e78-80. PubMed ID: 24566416
[TBL] [Abstract][Full Text] [Related]
9. Detectability of residual invasive bladder cancer in delayed
Higashiyama A; Komori T; Juri H; Inada Y; Azuma H; Narumi Y
Ann Nucl Med; 2018 Oct; 32(8):561-567. PubMed ID: 30014439
[TBL] [Abstract][Full Text] [Related]
10. Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study.
Mertens LS; Bruin NM; Vegt E; de Blok WM; Fioole-Bruining A; van Rhijn BW; Horenblas S; Vogel WV
Nucl Med Commun; 2012 Nov; 33(11):1195-201. PubMed ID: 22781846
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
14. Reduction of bladder activity on FDG PET/CT scan in patients with urinary bladder carcinoma. A prospective study with a patient-friendly protocol.
Tsai SC; Ou YC; Cheng CL; Li JR; Lin YC; Ho HC; Chiu KY; Su CK; Lin WY
Nuklearmedizin; 2015; 54(1):36-42. PubMed ID: 25345433
[TBL] [Abstract][Full Text] [Related]
15. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
16. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
17. Delayed imaging of the pelvis with diluted and filled bladder: a simple and efficient method in FDG PET/CT imaging of bladder carcinoma.
Halac M; Aliyev A; Yılmaz S; Ozhan M; Kaya R; Sağer S; Ergül N
Clin Nucl Med; 2012 Aug; 37(8):778-80. PubMed ID: 22785509
[TBL] [Abstract][Full Text] [Related]
18. Urinary bladder leiomyosarcoma: staging with 18F-FDG PET/CT.
Makis W; Rakheja R; Nahal A; Hickeson M; Lisbona R
Clin Nucl Med; 2013 May; 38(5):e218-22. PubMed ID: 23377410
[TBL] [Abstract][Full Text] [Related]
19. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
20. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
